Litcius/Paper detail

Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis

Gwénaël Le Teuff, Nathalie Cozic, Jean-Christophe Boyer, Valérie Boige, Robert B. Diasio, Julien Taı̈eb, Didier Meulendijks, Claire Palles, Matthias Schwab, Maarten J. Deenen, Carlo R. Largiadèr, Anthony M. Marinaki, Barbara Jennings, Yvonne Wettergren, Antonello Di Paolo, Eva Groß, Barna Budai, Stephen P. Ackland, André B. P. Kuilenburg, Howard L. McLeod, G. Milano, Fabienne Thomas, Marie‐Anne Loriot, David Kerr, Jan H.M. Schellens, Pierre Laurent‐Puig, Qian Shi, Jean‐Pierre Pignon, Marie-Christine Étienne-Grimaldi, FUSAFE collaborative group

2024British Journal of Cancer19 citationsDOIOpen Access PDF

Topics & Concepts

DPYDDihydropyrimidine dehydrogenaseMedicineToxicityInternal medicineClinical endpointConcomitantCapecitabineOncologyPharmacogeneticsConfidence intervalGastroenterologyClinical trialCancerGenotypeFluorouracilThymidylate synthaseBiologyGeneticsColorectal cancerGeneColorectal Cancer Treatments and StudiesBiochemical and Molecular ResearchBlood disorders and treatments